nach oben

Erschienen in:

17.06.2017 | Zervixkarzinom | Zertifizierte Fortbildung

Diagnostik und Therapie

Vorgehen bei Frauen mit primärem Zervixkarzinom

verfasst von: Dr. med. Christian Domröse, Prof. Dr. med. Peter Mallmann

Erschienen in: Im Fokus Onkologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch Früherkennungsmaßnahmen ist die Inzidenz des primären Zervixkarzinoms in den Industriestaaten rückläufig. Wird ein Zervixkarzinom diagnostiziert, bestimmen mehrere Kriterien das therapeutische Vorgehen, z. B. das FIGO-Stadium und der Lymphknotenstatus. Da auch jüngere Frauen betroffen sein können, ist zudem die Frage der Familienplanung ausschlaggebend.

Gustafsson L et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755–63.CrossRefPubMed

Zentrum für Krebsregisterdaten. Robert Koch-Institut, Berlin. 2016. www.krebsaten.de/abfrage (Datenstand: 03.11.2016).

Kjaer SK et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–88.CrossRefPubMedPubMedCentral

Walboomers JM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed

Schiffman M et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.CrossRefPubMed

Bosch FX et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(Suppl 10):K1–16.CrossRefPubMed

Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796–802.CrossRefPubMed

Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 2003;95(6):E2.CrossRefPubMed

Clifford G, Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer. 2008;122(7):1684–5.CrossRefPubMed

10.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.

11.

Schiffman M et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97(2):147–50.CrossRefPubMed

12.

Paavonen J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.CrossRefPubMed

13.

Garland SM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.CrossRefPubMed

14.

FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.CrossRef

15.

Joura EA et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.CrossRefPubMed

16.

FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438–46.CrossRef

17.

Joura EA, Giuliano AR, Iversen OE et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.CrossRefPubMed

18.

Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut — 2016/2017. Epidemiologisches Bulletin. 2016;34: www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/34_16.pdf?__blob=publicationFile (abgerufen am 24.5.2017)

19.

Gross G et al. S3-Leitlinie zur Impfprävention HPV-assoziierter Neoplasien. AWMF-Registernr.: 082/002.

20.

International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–95.CrossRef

21.

Gadducci A et al. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27(8):597–604.CrossRefPubMed

22.

International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.CrossRef

23.

Subak LL et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol. 1995;86(1):43–50.CrossRefPubMed

24.

Choi HJ et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer. 2006;106(4):914–22.CrossRefPubMed

25.

Hertel H et al. Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol. 2002;87(1):46–51.CrossRefPubMed

26.

Vidaurreta J et al. Laparoscopic staging in locally advanced cervical carcinoma: A new possible philosophy? Gynecol Oncol. 1999;75(3):366–71.CrossRefPubMed

27.

Marnitz S et al. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. Int J Radiat Oncol Biol Phys. 2016;94(2):243–53.CrossRefPubMed

28.

Marnitz S et al. Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol. 2007;183(9):473–8.CrossRefPubMed

29.

Goff BA et al. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol. 1999;74(3):436–42.CrossRefPubMed

30.

Gold MA et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer. 2008;112(9):1954–63.CrossRefPubMed

31.

S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion,1.0, 2014, AWMF-Registernummer: 032/033.

32.

Gadducci A et al. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008;66(1):10–20.CrossRefPubMed

33.

Hong JH et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(1):249–57.CrossRefPubMed

34.

Ries LAG MD, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, MD/USA: National Cancer Institute; 2007.

35.

Adegoke O et al. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012;21(10):1031–7.CrossRef

36.

Smith HO et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78(2):97–105.CrossRefPubMed

37.

Mitchell H et al. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer. 1995;71(4):894–7.CrossRefPubMedPubMedCentral

38.

Zappa M et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90(9):1784–6.PubMedPubMedCentral

39.

Bray F et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.CrossRefPubMed

40.

Spoozak L et al. Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol. 2012;206(1):80.e1–6.CrossRef

41.

Reade CJ et al. Surgery for early stage cervical cancer: how radical should it be? Gynecol Oncol. 2013;131(1):222–30.CrossRefPubMed

42.

Sonoda Y et al. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol. 2004;95(3):534–8.CrossRefPubMed

43.

Dargent D et al. La trachélectomie élargie: une alternative à l’hystérectomie radicale dans le traitement des cancers infiltrants développés sur la face externe du col utérin. Jobgyn 1994;2:285–92.

44.

Smith JR et al. Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol. 1997;104(10):1196–200.CrossRefPubMed

45.

Dargent D et al. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer. 2000;88(8):1877–82.CrossRefPubMed

46.

Lee CL et al. Laparoscopic radical trachelectomy for stage Ib1 cervical cancer. J Am Assoc Gynecol Laparosc. 2003;10(1):111–5.CrossRefPubMed

47.

Burnett AF et al. Robotic radical trachelectomy for preservation of fertility in early cervical cancer: case series and description of technique. J Minim Invasive Gynecol. 2009;16(5):569–72.CrossRefPubMed

48.

Roy M, Plante M. Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer. Am J Obstet Gynecol. 1998;179(6 Pt 1): 1491–6.CrossRefPubMed

49.

Sahdev A et al. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int J Gynecol Cancer. 2007;17(3):629–36.CrossRefPubMed

50.

Plante M et al. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol. 2011;121(2):290–7.CrossRefPubMed

51.

Speiser D et al. Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients. Int J Gynecol Cancer. 2011;21(9):1635–9.CrossRefPubMed

52.

Wertheim, E. The extended abdominal operation for carcinoma uteri (based on 500 operative cases). Am J Obstet Dis Women Child. 1912;66: 169–232.

53.

Meigs, JV. Carcinoma of the cervix—the Wertheim operation. Surg Gynecol Obstet. 1944;78: 95–8.

54.

Okabayashi H. Radical abdominal hysterectomy for cancer of the cervix uteri, modification of the Takayama operation. Surg Gynecol Obstet. 1921;33:335–41.

55.

Piver MS et al. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44(2):265–72.PubMed

56.

Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9(3):297–303.CrossRefPubMed

57.

Yabuki Y et al. Radical hysterectomy: An anatomic evaluation of parametrial dissection. Gynecol Oncol. 2000;77(1):155–63.CrossRefPubMed

58.

Yabuki Y et al. A new proposal for radical hysterectomy. Gynecol Oncol. 1996;62(3):370–8.CrossRefPubMed

59.

Höckel M. [Total mesometrial resection: nerve-sparing extended radical abdominal hysterectomy]. Zentralbl Gynakol. 2001;123(5):245–9.CrossRefPubMed

60.

Höckel M et al. Total mesometrial resection: high resolution nerve-sparing radical hysterectomy based on developmentally defined surgical anatomy. Int J Gynecol Cancer. 2003;13(6): 791–803.CrossRefPubMed

61.

Höckel M et al. Resection of the embryologically defined uterovaginal (Mullerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis. Lancet Oncol. 2009;10(7):683–92.CrossRefPubMed

62.

Juhasz-Böss I et al. Use of Laparoscopy in the Treatment of Endometrial and Cervical Cancer - Results of a 2012 Germany-wide Survey. Geburtshilfe Frauenheilkd. 2013;73(9):911–7.CrossRefPubMedPubMedCentral

63.

Dargent D, Mathevet P. [Radical laparoscopic vaginal hysterectomy]. J Gynecol Obstet Biol Reprod (Paris). 1992;21(6):709–10.

64.

Querleu D. Laparoscopically assisted radical vaginal hysterectomy. Gynecol Oncol. 1993;51(2):248–54.CrossRefPubMed

65.

Gottschalk E et al. Vaginal-assisted laparoscopic radical hysterectomy: rationale, technique, results. JSLS. 2011;15(4):451–9.CrossRefPubMedPubMedCentral

66.

Nezhat CR et al. Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection. Am J Obstet Gynecol. 1992;166(3):864–5.CrossRefPubMed

67.

Canis M et al. [Does endoscopic surgery have a role in radical surgery of cancer of the cervix uteri?]. J Gynecol Obstet Biol Reprod (Paris). 1990;19(7):921.

68.

Marchal F et al. Telerobotic-assisted laparoscopic hysterectomy for benign and oncologic pathologies: initial clinical experience with 30 patients. Surg Endosc. 2005;19(6):826–31.CrossRefPubMed

69.

Boggess JF. Robotic surgery in gynecologic oncology: evolution of a new surgical paradigm. J Robot Surg. 2007;1(1):31–7.CrossRefPubMedPubMedCentral

70.

van de Lande J et al. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol. 2007;106(3):604–13.CrossRefPubMed

71.

Kohler C et al. Explorative laparoscopy prior to exenterative surgery. Gynecol Oncol. 2002;86(3):311–5.CrossRefPubMed

72.

Marnitz S. Radioonkologische Aspekte des Zervixkarzinoms. Onkologe. 2016; 22(10):773–9.CrossRef

73.

Wang N et al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet. 2011;283(1):103–8.CrossRefPubMed

74.

Green J et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225.

75.

Rose PG et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.CrossRefPubMed

76.

Stehman FB et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197(5):503.e1–6.CrossRef

77.

Portelance L et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51(1):261–6.CrossRefPubMed

78.

Georg P et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2012;82(2):653–7.CrossRefPubMed

79.

Rydzewska L, Tierney J, Vale CL et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012 Dec 12;12:CD007406.PubMed

80.

Kim HS et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–24.CrossRefPubMed

81.

Monk BJ et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–55.CrossRefPubMedPubMedCentral

82.

Tewari KS et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.CrossRefPubMedPubMedCentral

83.

Pecorelli S et al. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–8.CrossRefPubMed

Titel: Diagnostik und Therapie
Vorgehen bei Frauen mit primärem Zervixkarzinom
verfasst von: Dr. med. Christian Domröse
Prof. Dr. med. Peter Mallmann
Publikationsdatum: 17.06.2017
Verlag: Springer Medizin
Schlagwörter: Zervixkarzinom
Zervixkarzinom
Konisation
Hysterektomie
Radikale Trachelektomie
Erschienen in: Im Fokus Onkologie / Ausgabe 6/2017
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI: https://doi.org/10.1007/s15015-017-2987-6

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Vorgehen bei Frauen mit primärem Zervixkarzinom

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Achtung, Artefakte!

CTGF-Blockade verhindert Fibrose

Erstes Rituximab-Biosimilar zugelassen

Bevacizumab bei Brustkrebs: Womit kombinieren?

Training nach Chemotherapie gegen kognitive Einschränkungen?

Topotecan beim platinsensitiven Ovarialkarzinom

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie